💊

Ambrisentan Viatris (previously Ambrisentan Mylan)

ambrisentan

Hypertension, Pulmonary

✅ Authorised Generic

✅

No active alerts

This medicine has no ongoing shortages, safety letters or recalls.

What it's used for

Ambrisentan Mylan is indicated for the treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease. Ambrisentan Mylan is indicated for the treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease.

⚠️ Patient safety

Official EMA page

https://www.ema.europa.eu/en/medicines/human/EPAR/ambrisentan-viatris